Background: The prognosis of patients diagnosed with locally advanced and metastatic gastric and esophago-gastric junction cancer is critical. The optimal choice of systemic therapy is essential to optimize survival outcomes. Methods: A comprehensive literature review via PubMed and analysis of major oncology congresses (European Society for Medical Oncology and American Society of Clinical Oncology websites) were conducted to ascertain the current status and latest developments in the systemic treatment of patients with localized or advanced gastric and esophago-gastric junction adenocarcinoma. Results: While neoadjuvant and perioperative chemotherapy for localized tumor stages is the preferred approach in the Western Hemisphere, adjuvant chemotherapy remains the preferred course of action in East Asia. The administration of chemotherapy, typically in the form of combinations comprising platinum and fluoropyrimidine compounds in combination with docetaxel, represents a standard of care. Investigations are underway into the potential of immunotherapy and other biologically targeted agents in the perioperative setting. To select the most appropriate therapy for advanced gastric cancer, including adenocarcinoma of the esophago-gastric junction, it is essential to determine biomarkers such as HER2 expression, PD-L1 combined positive score (CPS) (combined positive score), Claudin 18.2, and microsatellite instability (MSI). In the present clinical context, the standard first-line therapy is a combination of fluoropyrimidine and a platinum derivative. The selection of chemotherapy in combination with antibodies is contingent upon the specific biomarker under consideration. Conclusions: This article reviews the current state of the art based on recent clinical trial results and provides an outlook on the future of systemic therapy.

Department of Clinical Oncology Aichi Cancer Center Hospital Nagoya 464 8681 Japan

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University 656 53 Brno Czech Republic

Department of Haematology Oncology National University Cancer Institute Singapore 119074 Singapore

Department of Internal Medicine Yonsei Cancer Center Yonsei University College of Medicine Seoul 03722 Republic of Korea

Department of Medicine University of Leipzig Medical Center Cancer Center Central Germany 04103 Leipzig Germany

Zobrazit více v PubMed

Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. PubMed DOI

Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Tan P., Yeoh K.G. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015;149:1153–1162. doi: 10.1053/j.gastro.2015.05.059. PubMed DOI

Tramacere I., Negri E., Pelucchi C., Bagnardi V., Rota M., Scotti L., Islami F., Corrao G., La Vecchia C., Boffetta P. A meta-analysis on alcohol drinking and gastric cancer risk. Ann. Oncol. 2012;23:28–36. doi: 10.1093/annonc/mdr135. PubMed DOI

Lu L., Mullins C.S., Schafmayer C., Zeißig S., Linnebacher M. A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors. Cancer Commun. 2021;41:1137–1151. doi: 10.1002/cac2.12220. PubMed DOI PMC

Qiu H., Cao S., Xu R. Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41:1037–1048. doi: 10.1002/cac2.12197. PubMed DOI PMC

Wagner A.D., Syn N.L., Moehler M., Grothe W., Yong W.P., Tai B.C., Ho J., Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 2017;8:CD004064. doi: 10.1002/14651858.CD004064.pub4. PubMed DOI PMC

Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Corvera C., Das P., Denlinger C.S., Enzinger P.C., Fanta P., Farjah F., et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2019;17:855–883. doi: 10.6004/jnccn.2019.0033. PubMed DOI

Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Cooke D., Corvera C., Das P., Enzinger P.C., Enzler T., Fanta P., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. PubMed DOI

Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C., ESMO Guidelines Committee Electronic address: Clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;33:1005–1020. doi: 10.1016/j.annonc.2022.07.004. PubMed DOI

Obermannová R., Alsina M., Cervantes A., Leong T., Lordick F., Nilsson M., van Grieken N.C.T., Vogel A., Smyth E.C., ESMO Guidelines Committee Electronic address: Clinicalguidelines@esmo.org. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022;33:992–1004. doi: 10.1016/j.annonc.2022.07.003. PubMed DOI

Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. PubMed DOI

Ychou M., Boige V., Pignon J.P., Conroy T., Bouché O., Lebreton G., Ducourtieux M., Bedenne L., Fabre J.M., Saint-Aubert B., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011;29:1715–1721. doi: 10.1200/JCO.2010.33.0597. PubMed DOI

Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., et al. FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393:1948–1957. PubMed

Japanese Gastric Cancer Association . Japanese Gastric Cancer Treatment Guidelines 2021. 6th ed. Volume 26. Japanese Gastric Cancer Association; Kyoto, Japan: 2023. pp. 1–25. PubMed PMC

Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007;357:1810–1820. doi: 10.1056/NEJMoa072252. PubMed DOI

Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T., Nashimoto A., Fujii M., Nakajima T., Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011;29:4387–4393. doi: 10.1200/JCO.2011.36.5908. PubMed DOI

Bang Y.J., Kim Y.W., Yang H.K., Chung H.C., Park Y.K., Lee K.H., Lee K.W., Kim Y.H., Noh S.I., Cho J.Y., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–321. doi: 10.1016/S0140-6736(11)61873-4. PubMed DOI

Yoshida K., Kodera Y., Kochi M., Ichikawa W., Kakeji Y., Sano T., Nagao N., Takahashi M., Takagane A., Watanabe T., et al. Addition of docetaxel to Oral Fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J. Clin. Oncol. 2019;37:1296–1304. doi: 10.1200/JCO.18.01138. PubMed DOI PMC

Park S.H., Lim D.H., Sohn T.S., Lee J., Zang D.Y., Kim S.T., Kang J.H., Oh S.Y., Hwang I.G., Ji J.H., et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: The ARTIST 2 trial. Ann. Oncol. 2021;32:368–374. doi: 10.1016/j.annonc.2020.11.017. PubMed DOI

Shitara K., Rha S.Y., Wyrwicz L.S., Oshima T., Karaseva N., Osipov M., Yasui H., Yabusaki H., Afanasyev S., Park Y.K., et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212–224. doi: 10.1016/S1470-2045(23)00541-7. PubMed DOI

Janjigian Y.Y., Al-Batran S.E., Wainberg Z.A., Van Cutsem E., Molena D., Muro K., Hyung W.J., Wyrwicz L.S., Oh D.Y., Omori T., et al. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Ann. Oncol. 2023;34:S1315–S1316. doi: 10.1016/j.annonc.2023.10.074. DOI

Lorenzen S., Götze T.O., Thuss-Patience P., Biebl M., Homann N., Schenk M., Lindig U., Heuer V., Kretzschmar A., Goekkurt E., et al. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. J. Clin. Oncol. 2024;42:410–420. doi: 10.1200/JCO.23.00975. PubMed DOI

Kang Y.K., Terashima M., Kim Y.W., Boku N., Chung H.C., Chen J.S., Ji J., Yeh T.S., Chen L.T., Ryu M.H., et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 2024;9:705–717. PubMed

Pietrantonio F., Miceli R., Raimondi A., Kim Y.W., Kang W.K., Langley R.E., Choi Y.Y., Kim K.M., Nankivell M.G., Morano F., et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J. Clin. Oncol. 2019;37:3392–3400. doi: 10.1200/JCO.19.01124. PubMed DOI

Pietrantonio F., Randon G., Di Bartolomeo M., Luciani A., Chao J., Smyth E.C., Petrelli F. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: A meta-analysis of randomized clinical trials. ESMO Open. 2021;6:100036. doi: 10.1016/j.esmoop.2020.100036. PubMed DOI PMC

André T., Tougeron D., Piessen G., de la Fouchardière C., Louvet C., Adenis A., Jary M., Tournigand C., Aparicio T., Desrame J., et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J. Clin. Oncol. 2023;41:255–265. doi: 10.1200/JCO.22.00686. PubMed DOI PMC

Pietrantonio F., Raimondi A., Lonardi S., Murgioni S., Cardellino G.G., Tamberi S., Strippoli A., Palermo F., Prisciandaro M., Randon G., et al. INFINITY: A multicentre single-arm multi-cohort phase II trial of tremelimumab durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC) J. Clin. Oncol. 2023;41((Suppl. S4)):358. doi: 10.1200/JCO.2023.41.4_suppl.358. DOI

Hofheinz R.D., Hegewisch-Becker S., Kunzmann V., Thuss-Patience P., Fuchs M., Homann N., Graeven U., Schulte N., Merx K., Pohl M., et al. Trastuzumab in combination with 5-fluorouracil leucovorin oxaliplatin docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int. J. Cancer. 2021;149:1322–1331. PubMed

Al-Batran S.E., Haag G.M., Ettrich T.J., Borchert K., Kretzschmar A., Teschendorf C., Siegler G.M., Ebert M., Goekkurt E., Welslau M.K., et al. 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. Ann. Oncol. 2020;31:S899. doi: 10.1016/j.annonc.2020.08.1927. DOI

Wagner A.D., Grabsch H.I., Mauer M., Fumagalli Romario U., Kang Y.K., Bouche O., Lorenzen S., Moehler M.H., Thuss-Patience P.C., Elme A., et al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. J. Clin. Oncol. 2023;41((Suppl. 16)):4057. PubMed

Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. Erratum in Lancet 2010, 376, 1302. PubMed DOI

Haffner I., Schierle K., Raimúndez E., Geier B., Maier D., Hasenauer J., Luber B., Walch A., Kolbe K., Riera Knorrenschild J., et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J. Clin. Oncol. 2021;39:1468–1478. doi: 10.1200/JCO.20.02761. PubMed DOI PMC

Park Y., Nam S.K., Seo S.H., Park K.U., Oh H.J., Park Y.S., Suh Y.S., Ahn S.H., Park D.J., Kim H.H., et al. Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. J. Gastric. Cancer. 2023;23:264–274. doi: 10.5230/jgc.2023.23.e5. PubMed DOI PMC

Rüschoff J., Schildhaus H.U., Rüschoff J.H., Jöhrens K., Bocker Edmonston T., Dietmaier W., Bläker H., Baretton G., Horst D., Dietel M., et al. Testing for deficient mismatch repair and microsatellite instability: A focused update. Pathologie. 2023;44((Suppl. S2)):61–70. doi: 10.1007/s00292-023-01208-2. PubMed DOI PMC

Baretton G.B., Lordick F., Interdisciplinary Expert Group. Gaiser T., Hofheinz R., Horst D., Lorenzen S., Moehler M., Röcken C., Schirmacher P., et al. Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J. Cancer Res. Clin. Oncol. 2023;149:16231–16238. doi: 10.1007/s00432-023-05180-5. PubMed DOI PMC

Sahin U., Türeci Ö., Manikhas G., Lordick F., Rusyn A., Vynnychenko I., Dudov A., Bazin I., Bondarenko I., Melichar B., et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 2021;32:609–619. doi: 10.1016/j.annonc.2021.02.005. PubMed DOI

Shitara K., Lordick F., Bang Y.J., Enzinger P., Ilson D., Shah M.A., Van Cutsem E., Xu R.H., Aprile G., Xu J., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–1668. doi: 10.1016/S0140-6736(23)00620-7. PubMed DOI

Shah M.A., Shitara K., Ajani J.A., Bang Y.J., Enzinger P., Ilson D., Lordick F., Van Cutsem E., Gallego Plazas J., Huang J., et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 2023;29:2133–2141. doi: 10.1038/s41591-023-02465-7. PubMed DOI PMC

Kubota Y., Kawazoe A., Mishima S., Nakamura Y., Kotani D., Kuboki Y., Bando H., Kojima T., Doi T., Yoshino T., et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762. doi: 10.1016/j.esmoop.2022.100762. PubMed DOI PMC

Hall P.S., Swinson D., Cairns D.A., Waters J.S., Petty R., Allmark C., Ruddock S., Falk S., Wadsley J., Roy R., et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7:869–877. doi: 10.1001/jamaoncol.2021.0848. PubMed DOI PMC

Janjigian Y.Y., Shitara K., Moehler M., Garrido M., Salman P., Shen L., Wyrwicz L., Yamaguchi K., Skoczylas T., Campos Bragagnoli A., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. doi: 10.1016/S0140-6736(21)00797-2. PubMed DOI PMC

Rha S.Y., Oh D.Y., Yañez P., Bai Y., Ryu M.H., Lee J., Rivera F., Alves G.V., Garrido M., Shiu K.K., et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181–1195. doi: 10.1016/S1470-2045(23)00515-6. PubMed DOI

Yoon H.H., Jin Z., Kour O., Kankeu Fonkoua L.A., Shitara K., Gibson M.K., Prokop L.J., Moehler M., Kang Y.K., Shi Q., et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022;8:1456–1465. doi: 10.1001/jamaoncol.2022.3707. PubMed DOI PMC

Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., Lyon A.R., Wick W., Kostine M., Peters S., et al. Electronic address: Clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–1238. doi: 10.1016/j.annonc.2022.10.001. PubMed DOI

Janjigian Y.Y., Kawazoe A., Bai Y., Xu J., Lonardi S., Metges J.P., Yanez P., Wyrwicz L.S., Shen L., Ostapenko Y., et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197–2208. doi: 10.1016/S0140-6736(23)02033-0. PubMed DOI

Shitara K., Bang Y.J., Iwasa S., Sugimoto N., Ryu M.H., Sakai D., Chung H.C., Kawakami H., Yabusaki H., Lee J., et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 2020;382:2419–2430. doi: 10.1056/NEJMoa2004413. PubMed DOI

Van Cutsem E., di Bartolomeo M., Smyth E., Chau I., Park H., Siena S., Lonardi S., Wainberg Z.A., Ajani J., Chao J., et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744–756. PubMed PMC

Makiyama A., Sukawa Y., Kashiwada T., Kawada J., Hosokawa A., Horie Y., Tsuji A., Moriwaki T., Tanioka H., Shinozaki K., et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study) J. Clin. Oncol. 2020;38:1919–1927. doi: 10.1200/JCO.19.03077. PubMed DOI

Wekking D., Porcu M., Pellegrino B., Lai E., Mura G., Denaro N., Saba L., Musolino A., Scartozzi M., Solinas C. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8:102043. doi: 10.1016/j.esmoop.2023.102043. PubMed DOI PMC

Shimozaki K., Fukuoka S., Ooki A., Yamaguchi K. HER2-low gastric cancer: Is the subgroup targetable? ESMO Open. 2024;9:103679. doi: 10.1016/j.esmoop.2024.103679. PubMed DOI PMC

Kawakami H., Hironaka S., Esaki T., Chayama K., Tsuda M., Sugimoto N., Kadowaki S., Makiyama A., Machida N., Hirano H., et al. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7) Cancers. 2021;13:805. doi: 10.3390/cancers13040805. PubMed DOI PMC

Shitara K., Ajani J.A., Moehler M., Garrido M., Gallardo C., Shen L., Yamaguchi K., Wyrwicz L., Skoczylas T., Bragagnoli A.C., et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942–948. doi: 10.1038/s41586-022-04508-4. PubMed DOI PMC

Shitara K., Van Cutsem E., Bang Y.J., Fuchs C., Wyrwicz L., Lee K.W., Kudaba I., Garrido M., Chung H.C., Lee J., et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1571–1580. doi: 10.1001/jamaoncol.2020.3370. PubMed DOI PMC

Marabelle A., Cassier P.A., Fakih M., Kao S., Nielsen D., Italiano A., Guren T.K., van Dongen M.G.J., Spencer K., Bariani G.M., et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol. Hepatol. 2022;7:446–454. doi: 10.1016/S2468-1253(21)00382-4. PubMed DOI PMC

Lordick F., Van Cutsem E., Shitara K., Xu R.H., Ajani J.A., Shah M.A., Oh M., Ganguli A., Chang L., Rhoten S., et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024;9:103663. doi: 10.1016/j.esmoop.2024.103663. PubMed DOI PMC

Klempner S.J., Lee K.W., Shitara K., Metges J.P., Lonardi S., Ilson D.H., Fazio N., Kim T.Y., Bai L.Y., Moran D., et al. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clin. Cancer Res. 2023;29:3882–3891. doi: 10.1158/1078-0432.CCR-23-0204. PubMed DOI PMC

Nakayama I., Qi C., Chen Y., Nakamura Y., Shen L., Shitara K. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 2024;21:354–369. doi: 10.1038/s41571-024-00874-2. PubMed DOI

Gordon A., Johnston E., Lau D.K., Starling N. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. Onco. Targets Ther. 2022;15:1183–1196. doi: 10.2147/OTT.S282718. PubMed DOI PMC

Wainberg Z.A., Enzinger P.C., Kang Y.K., Qin S., Yamaguchi K., Kim I.H., Saeed A., Oh S.C., Li J., Turk H.M., et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23:1430–1440. doi: 10.1016/S1470-2045(22)00603-9. PubMed DOI

Wilke H., Muro K., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y., Hironaka S., Sugimoto N., Lipatov O., Kim T.Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. doi: 10.1016/S1470-2045(14)70420-6. PubMed DOI

Lorenzen S., Thuss-Patience P., Pauligk C., Gökkurt E., Ettrich T., Lordick F., Stahl M., Reichardt P., Sökler M., Pink D., et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel–results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur. J. Cancer. 2022;165:48–57. PubMed

Lam L.L., Pavlakis N., Shitara K., Sjoquist K.M., Martin A.J., Yip S., Kang Y.K., Bang Y.J., Chen L.T., Moehler M., et al. INTEGRATE II: Randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): A study by the Australasian Gastro-Intestinal Trials Group (AGITG) BMC Cancer. 2023;23:180. doi: 10.1186/s12885-023-10642-7. PubMed DOI PMC

Ambrosini M., Del Re M., Manca P., Hendifar A., Drilon A., Harada G., Ree A.H., Klempner S., Mælandsmo G.M., Flatmark K., et al. ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precis. Oncol. 2022;6:e2200015. doi: 10.1200/PO.22.00015. PubMed DOI PMC

Chon H.J., Kim H.R., Shin E., Kim C., Heo S.J., Lee C.K., Park J.K., Noh S.H., Chung H.C., Rha S.Y. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Ann. Surg. Oncol. 2015;22:3938–3945. doi: 10.1245/s10434-015-4376-8. PubMed DOI

Deng N., Goh L.K., Wang H., Das K., Tao J., Tan I.B., Zhang S., Lee M., Wu J., Lim K.H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–684. doi: 10.1136/gutjnl-2011-301839. PubMed DOI PMC

Catenacci D.V., Moya S., Lomnicki S., Chase L.M., Peterson B.F., Reizine N., Alpert L., Setia N., Xiao S.Y., Hart J., et al. Personalized Antibodies for Gas-troesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Meta-static Disease. Cancer Discov. 2021;11:308–325. doi: 10.1158/2159-8290.CD-20-1408. PubMed DOI PMC

Ebert K., Haffner I., Zwingenberger G., Keller S., Raimúndez E., Geffers R., Wirtz R., Barbaria E., Hollerieth V., Arnold R., et al. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—The role of HAS2, SHB and HBEGF. BMC Cancer. 2022;22:254. doi: 10.1186/s12885-022-09335-4. PubMed DOI PMC

Lordick F., Kang Y.K., Chung H.C., Salman P., Oh S.C., Bodoky G., Kurteva G., Volovat C., Moiseyenko V.M., Gorbunova V., et al. Capecitabine and cisplatin with or without cetuxi-mab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–499. doi: 10.1016/S1470-2045(13)70102-5. PubMed DOI

Moehler M., Mueller A., Trarbach T., Lordick F., Seufferlein T., Kubicka S., Geissler M., Schwarz S., Galle P.R., Kanzler S., et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study. Ann. Oncol. 2011;22:1358–1366. doi: 10.1093/annonc/mdq591. PubMed DOI

Lennerz J.K., Kwak E.L., Ackerman A., Michael M., Fox S.B., Bergethon K., Lauwers G.Y., Christensen J.G., Wilner K.D., Haber D.A., et al. MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. JCO. 2011;29:4803–4810. doi: 10.1200/JCO.2011.35.4928. PubMed DOI PMC

Bahleda R., Italiano A., Hierro C., Mita A., Cervantes A., Chan N., Awad M., Calvo E., Moreno V., Govindan R., et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin. Cancer Res. 2019;25:4888–4897. doi: 10.1158/1078-0432.CCR-18-3334. PubMed DOI

Cha Y., Kim H.-P., Lim Y., Han S.-W., Song S.-H., Kim T.-Y. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. Mol. Oncol. 2018;12:993–1003. doi: 10.1002/1878-0261.12194. PubMed DOI PMC

Bekaii-Saab T.S., Valle J.W., Van Cutsem E., Rimassa L., Furuse J., Ioka T., Melisi D., Macarulla T., Bridgewater J., Wasan H., et al. FIGHT-302: First-line pemigatinib vs gem-citabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020;16:2385–2399. doi: 10.2217/fon-2020-0429. PubMed DOI PMC

Betts G., Valentine H., Pritchard S., Swindell R., Williams V., Morgan S., Griffiths E.A., Welch I., West C., Womack C. FGFR2, HER2 and cMet in gastric adenocar-cinoma: Detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch. 2014;464:145–156. doi: 10.1007/s00428-013-1517-y. PubMed DOI

Weaver A., Bossaer J.B. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. J. Oncol. Pharm Pr. 2021;27:702–710. doi: 10.1177/1078155220983425. PubMed DOI

Helsten T., Elkin S., Arthur E., Tomson B.N., Carter J., Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin. Cancer Res. 2016;22:259–267. doi: 10.1158/1078-0432.CCR-14-3212. PubMed DOI

Merz V., Zecchetto C., Simionato F., Cavaliere A., Casalino S., Pavarana M., Giacopuzzi S., Bencivenga M., Tomezzoli A., Santoro R., et al. A phase II trial of the FGFR inhibitor pem-igatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: The FiGhTeR trial. Ther. Adv. Med. Oncol. 2020;12:1758835920937889. doi: 10.1177/1758835920937889. PubMed DOI PMC

Alexandrov L.B., Nik-Zainal S., Siu H.C., Leung S.Y., Stratton M.R. A mutational signature in gastric cancer suggests therapeu-tic strategies. Nat. Commun. 2015;6:8683. doi: 10.1038/ncomms9683. PubMed DOI PMC

Bang Y.J., Xu R.H., Chin K., Lee K.W., Park S.H., Rha S.Y., Shen L., Qin S., Xu N., Im S.A., et al. Olaparib in combination with paclitaxel in patients with ad-vanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1637–1651. doi: 10.1016/S1470-2045(17)30682-4. PubMed DOI

Petrelli A., Rizzolio S., Pietrantonio F., Bellomo S.E., Benelli M., De Cecco L., Romagnoli D., Berrino E., Orrù C., Ribisi S., et al. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Cancer Res. 2023;83:1699–1710. doi: 10.1158/0008-5472.CAN-22-2620. PubMed DOI PMC

Secrier M., Li X., De Silva N., Eldridge M.D., Contino G., Bornschein J., MacRae S., Grehan N., O’Donovan M., Miremadi A., et al. Mutational signatures in esophageal adeno-carcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 2016;48:1131–1141. doi: 10.1038/ng.3659. PubMed DOI PMC

Bekaii-Saab T.S., Yaeger R., Spira A.I., Pelster M.S., Sabari J.K., Hafez N., Barve M., Velastegui K., Yan X., Shetty A., et al. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J. Clin. Oncol. 2023;41:4097–4106. doi: 10.1200/JCO.23.00434. PubMed DOI PMC

Salem M.E., El-Refai S.M., Sha W., Puccini A., Grothey A., George T.J., Hwang J.J., O’Neil B., Barrett A.S., Kadakia K.C., et al. Landscape of KRASG12C, Associated Ge-nomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precis. Oncol. 2022;6:e2100245. doi: 10.1200/PO.21.00245. PubMed DOI PMC

Aparicio T., Cozic N., de La Fouchardière C., Meriaux E., Plaza J., Mineur L., Guimbaud R., Samalin E., Mary F., Lecomte T., et al. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program. Target Oncol. 2021;16:381–388. doi: 10.1007/s11523-021-00811-8. PubMed DOI PMC

Lee J., Tran P., Klempner S.J. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach. Clin. Oncol. 2016;28:e35–e44. doi: 10.1016/j.clon.2016.01.009. PubMed DOI

Lee J., Kim S.T., Kim K., Lee H., Kozarewa I., Mortimer P.G., Odegaard J.I., Harrington E.A., Lee J., Lee T., et al. Tumor Genomic Profiling Guides Patients with Metastat-ic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov. 2019;9:1388–1405. doi: 10.1158/2159-8290.CD-19-0442. PubMed DOI

Akimoto E., Kuwata T., Shitara K., Kawazoe A., Sakamoto N., Ishii G., Ochiai A., Kinoshita T. Impact of Programmed Death-Ligand 1 Expres-sion on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gas-tric Cancer After Surgery. Ann. Surg. Oncol. 2023;30:5227–5236. doi: 10.1245/s10434-023-13266-0. PubMed DOI

Derks S., Liao X., Chiaravalli A.M., Xu X., Camargo M.C., Solcia E., Sessa F., Fleitas T., Freeman G.J., Rodig S.J., et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7:32925–32932. doi: 10.18632/oncotarget.9076. PubMed DOI PMC

Kim S.T., Cristescu R., Bass A.J., Kim K.M., Odegaard J.I., Kim K., Liu X.Q., Sher X., Jung H., Lee M., et al. Comprehensive molecular characterization of clini-cal responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 2018;24:1449–1458. doi: 10.1038/s41591-018-0101-z. PubMed DOI

van Der Sluis K., van Sandick J.W., van Dieren J.M., Vollebergh M.A., Grootscholten C., van den Berg J.G., Snaebjornsson P., Hartemink K.J., Veenhof A.A., Chalabi M., et al. The clinical impact of testing for biomarkers in gastric cancer patients: A real-world cohort. Histopathology. 2023;82:826–836. doi: 10.1111/his.14869. PubMed DOI

Chalmers Z.R., Connelly C.F., Fabrizio D., Gay L., Ali S.M., Ennis R., Schrock A., Campbell B., Shlien A., Chmielecki J., et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. PubMed PMC

Shitara K., Özgüroğlu M., Bang Y.J., Di Bartolomeo M., Mandalà M., Ryu M.H., Caglevic C., Chung H.C., Muro K., Van Cutsem E., et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesoph-ageal adenocarcinoma. Ann. Oncol. 2021;32:1127–1136. doi: 10.1016/j.annonc.2021.05.803. PubMed DOI